A new opportunity to diagnose prostate cancer in MCSC
NewsThe MCSC named after A.S. Loginov expands diagnostic opportunities for patients. Since November 2025, PET has been performed in the Department of Radioisotope diagnostics/CT with PSMA is one of the most modern and accurate methods for detecting prostate cancer.
- What is PET/CT with PSMA?
This is a highly informative study that allows you to see even the smallest tumor foci. A special radiopharmaceutical binds to PSMA— a protein that is present in large quantities on prostate cancer cells. Thanks to this, doctors get the most accurate picture of the disease.
- When is the study applied?
PET/CT with PSMA is used at different stages of the disease and helps:
— detect a recurrence of the disease with an increase in PSA from 0.2 ng / ml;
— to clarify the stage of the disease in high-risk patients;
— evaluate the effectiveness of treatment and adjust further tactics.
- Why is it important for the patient?
— More accurate diagnosis.
— The ability to detect the disease in the early stages.
— Personal approach to treatment and monitoring of its results.
PET research/CT with PSMA can be performed under a contract for paid medical services or under a VHI policy.
Detailed information is available at the link.
